D. FitzGerald

发表

Functional domains of pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli

I. Pastan, S. Adhya, Jaulang Hwang, 1987, Cell.

Cytotoxic Effects of a Recombinant Chimeric Toxin on Rapidly Proliferating Vascular Smooth Muscle Cells

I. Pastan, S. Epstein, S. Biro, 1991, Circulation.

Smooth Muscle Cells

I. Pastan, S. Epstein, S. Biro, 2005 .

Immunotoxins for leukemia.

I. Pastan, R. Kreitman, A. Wayne, 2014, Blood.

Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells.

S. Hewitt, M. Gadina, N. Simon, 2019, JCI insight.

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

I. Pastan, R. Kreitman, R. Hassan, 2009, Clinical Cancer Research.

Anti-CD 22 Immunotoxin RFB 4 ( dsFv )-PE 38 ( BL 22 ) for CD 22-Positive Hematologic Malignancies of Childhood : Preclinical Studies and Phase I Clinical Trial

S. Steinberg, I. Pastan, H. Findley, 2010 .

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial

S. Steinberg, I. Pastan, H. Findley, 2010, Clinical Cancer Research.

Mutation at the Processing Site of Chicken Low Density Lipoprotein Receptor-related Protein Impairs Efficient Endoplasmic Reticulum Exit, but Proteolytic Cleavage Is Not Essential for Its Endocytic Functions*

R. McLeod, J. Nimpf, K. Ko, 1998, The Journal of Biological Chemistry.

Ranking Differential Drug Activities from Dose-Response Synthetic Lethality Screens

M. Ferrer, I. Pastan, R. Guha, 2016, Journal of biomolecular screening.

LRP 1 B functions as a receptor for Pseudomonas exotoxin.

G. Bu, D. Pastrana, Jane M. Knisely, 2005, Biochimica et biophysica acta.

Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy

I. Pastan, O. Chertov, Laiman Xiang, 2012, Proceedings of the National Academy of Sciences.

Complete regression of human B‐cell lymphoma xenografts in mice treated with recombinant anti‐CD22 immunotoxin RFB4(dsFv)‐PE38 at doses tolerated by cynomolgus monkeys

I. Pastan, R. Kreitman, Qing-cheng Wang, 1999, International journal of cancer.

Recombinant RFB4 immunotoxins exhibit potent cytotoxic activity for CD22-bearing cells and tumors.

I. Pastan, E. Mansfield, P. Amlot, 1997, Blood.

Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies.

W. Wilson, I. Pastan, M. Stetler-Stevenson, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.

W. Wilson, I. Pastan, M. Tallman, 2018, Blood.

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia.

W. Wilson, I. Pastan, R. Lechleider, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotoxins with decreased immunogenicity and improved activity

I. Pastan, R. Kreitman, M. Onda, 2011, Leukemia & lymphoma.

Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia

W. Wilson, I. Pastan, M. Stetler-Stevenson, 2011, Leukemia & lymphoma.

ABT-737 Overcomes Resistance to Immunotoxin-Mediated Apoptosis and Enhances the Delivery of Pseudomonas Exotoxin–Based Proteins to the Cell Cytosol

Elizabeth Moskatel, Roberta Traini, A. Antignani, 2010, Molecular Cancer Therapeutics.

Pseudomonas Exotoxin A-Mediated Apoptosis Is Bak Dependent and Preceded by the Degradation of Mcl-1

I. Pastan, R. Youle, Xing-yan Du, 2010, Molecular and Cellular Biology.

Approach to the patient after relapse of hairy cell leukemia

I. Pastan, R. Kreitman, D. FitzGerald, 2009, Leukemia & lymphoma.

Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia.

W. Wilson, I. Pastan, M. Stetler-Stevenson, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Differential cellular internalization of anti-CD19 and -CD22 immunotoxins results in different cytotoxic activity.

I. Pastan, R. Beers, Xing-yan Du, 2008, Cancer research.

A nonradioactive, cell-free method for measuring protein synthesis inhibition by Pseudomonas exotoxin.

D. Pastrana, D. FitzGerald, 2006, Analytical biochemistry.

PatientsImmunotoxins for the Treatment of Cancer Exotoxin (PE38) Used to Make Pseudomonas Associated with a Truncated Form of Characterization of the B Cell Epitopes

James J. Vincent, I. Pastan, Byungkook Lee, 2006 .

Cleavage of pseudomonas exotoxin and diphtheria toxin by a furin-like enzyme prepared from beef liver.

M. Chiron, C. Fryling, D. FitzGerald, 1994, The Journal of biological chemistry.

Cell-mediated cleavage of Pseudomonas exotoxin between Arg279 and Gly280 generates the enzymatically active fragment which translocates to the cytosol.

I. Pastan, C. Fryling, M. Ogata, 1992, The Journal of biological chemistry.

Antitumor Activity of a Transforming Growth Factor a-Pseudomonas Exotoxin Fusion Protein (TGF-a-PE40)

I. Pastan, L. Pai, D. FitzGerald, 2006 .

Processing of Pseudomonas exotoxin by a cellular protease results in the generation of a 37,000-Da toxin fragment that is translocated to the cytosol.

I. Pastan, D. Fitzgerald, V. Chaudhary, 1990, The Journal of biological chemistry.

TGFα-anti-Tac(Fv)-PE40: A bifunctional toxin cytotoxic for cells with EGF or IL2 receptors

I. Pastan, V. Chaudhary, J. Batra, 1990 .

A recombinant immunotoxin consisting of two antibody variable domains fused to Pseudomonas exotoxin

T. Waldmann, I. Pastan, V. Chaudhary, 1989, Nature.

Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin

Jingli Zhang, M. Makowski, R. Hassan, 2010, Cancer Immunology, Immunotherapy.

Antitumor Effects of Immunotoxins Are Enhanced by Lowering HCK or Treatment with Src Kinase Inhibitors

I. Pastan, Laiman Xiang, Xiu-fen Liu, 2013, Molecular Cancer Therapeutics.

Efficiency of Immunotoxin Cytotoxicity Is Modulated by the Intracellular Itinerary

I. Pastan, F. Maxfield, S. Mukherjee, 2012, PloS one.

Expressing the Human T Cell Growth Factor Receptor

T. Waldmann, M. Willingham, D. FitzGerald, 1984 .

A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox: Phase I Study in Pediatric Acute Lymphoblastic Leukemia (ALL)

C. Pui, I. Pastan, L. Silverman, 2011 .

The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds and internalizes Pseudomonas exotoxin A.

D. Strickland, M. Thompson, R. Morris, 1992, The Journal of biological chemistry.

The 39-kDa receptor-associated protein regulates ligand binding by the very low density lipoprotein receptor.

D. Strickland, J. Strauss, W. Argraves, 1994, The Journal of biological chemistry.

Pseudomonas exotoxin-mediated selection yields cells with altered expression of low-density lipoprotein receptor-related protein [published erratum appears in J Cell Biol 1995 Aug;130(4):1015]

S. Leppla, D. Strickland, J. Winkles, 1995, The Journal of cell biology.

Intranasal Immunization Strategy To Impede Pilin-Mediated Binding of Pseudomonas aeruginosa to Airway Epithelial Cells

R. Mrsny, D. Dean, F. Huang, 2005, Infection and Immunity.

Cell-specific toxicity of a chimeric protein composed of interleukin-6 and Pseudomonas exotoxin (IL6-PE40) on tumor cells

I. Pastan, R. Nordan, C. Siegall, 1990 .

Monoclonal antibodies and immobilized antibodies

C. A. White, R. Krauss, M. Melamed, 1987 .

TGFα-PE40 inhibits non-small cell lung cancer growth

I. Pastan, T. Moody, C. Siegall, 1994 .

Level of receptor-associated protein moderates cellular susceptibility to pseudomonas exotoxin A

D. Strickland, R. Morris, C. Saelinger, 1995, Infection and immunity.

Selection of Pseudomonas Exotoxin—Resistant Cells with Altered Expression of α2MR/LRP

S. Leppla, D. Strickland, M. Kounnas, 1994 .

Dissection of receptor folding and ligand-binding property with functional minireceptors of LDL receptor-related protein.

A. Schwartz, G. Bu, Y. Li, 2001, Journal of cell science.

Divergent Pseudomonas exotoxin A sensitivity in normal and transformed liver cells is correlated with low-density lipoprotein receptor-related protein expression.

J. LaMarre, W. Marshall, S. Benn, 2001, Toxicon : official journal of the International Society on Toxinology.

Enhanced Macrophage Resistance toPseudomonas Exotoxin A Is Correlated with Decreased Expression of the Low-Density Lipoprotein Receptor-Related Protein

J. LaMarre, J. Yamate, S. Benn, 1999, Infection and Immunity.

Ligand-toxin Hybrids Directed to the -Macroglobulin Receptor/Low Density Lipoprotein Receptor-related Protein Exhibit Lower Toxicity than Native Pseudomonas Exotoxin (*)

D. Strickland, D. FitzGerald, A. Zdanovsky, 1996, The Journal of Biological Chemistry.

Mammalian cell expression of an active site mutant of Pseudomonas exotoxin disrupts LRP1 maturation.

M. McKee, C. Yun, D. Pastrana, 2008, Journal of biomedical science.

Procedures for measuring receptor-mediated binding and internalization of human interferon.

K. Zoon, H. Arnheiter, D. FitzGerald, 1986, Methods in enzymology.

Adenovirus Entry into Cells: Some New Observations on an Old Problem

I. Pastan, M. Willingham, P. Seth, 1986 .

Human interferon alpha enters cells by receptor-mediated endocytosis.

M. Willingham, K. Zoon, D. zur Nedden, 1983, Virology.

Inhibition of the activity of pseudomonas toxin by methylamine.

R. Morris, C. Saelinger, D. FitzGerald, 1983, Reviews of infectious diseases.

Essential role of calcium in cellular internalization of Pseudomonas toxin

R. Morris, C. Saelinger, D. FitzGerald, 1982, Infection and immunity.

Receptor-mediated internalization of pseudomonas toxin by mouse fibroblasts

R. Morris, C. Saelinger, D. FitzGerald, 1980, Cell.

Barnase toxin: A new chimeric toxin composed of pseudomonas exotoxin A and barnase

I. Pastan, T. I. Prior, D. FitzGerald, 1991, Cell.

Proteolytic Cleavage of a C-terminal Prosequence, Leading to Autoprocessing at the N Terminus, Activates Leucine Aminopeptidase from Pseudomonas aeruginosa*

A. Antignani, D. Pastrana, R. Hertle, 2009, Journal of Biological Chemistry.

Anticancer Effects of Mesothelin-Targeted Immunotoxin Therapy Are Regulated by Tyrosine Kinase DDR1.

Scott E. Martin, I. Pastan, M. Prunotto, 2016, Cancer Research.

A recombinant single-chain immunotoxin composed of anti-Tac variable regions and a truncated diphtheria toxin.

I. Pastan, V. Chaudhary, M. Gallo, 1990, Proceedings of the National Academy of Sciences of the United States of America.

IL2-PE664Glu, a new chimeric protein cytotoxic to human-activated T lymphocytes.

T. Waldmann, I. Pastan, R. Clark, 1990, The Journal of biological chemistry.

The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.

T. Waldmann, I. Pastan, M. Willingham, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Cytotoxic activity of a recombinant fusion protein between interleukin 4 and Pseudomonas exotoxin.

I. Pastan, V. Chaudhary, M. Ogata, 1989, Proceedings of the National Academy of Sciences of the United States of America.

ABT-737 Promotes the Dislocation of ER Luminal Proteins to the Cytosol, Including Pseudomonas Exotoxin

A. Antignani, D. FitzGerald, R. Sarnovsky, 2014, Molecular Cancer Therapeutics.

to Protein Therapeutics in Murine Hosts Tofacitinib Suppresses Antibody Responses

I. Pastan, J. O’Shea, K. Ghoreschi, 2014 .

Releasable PEGylation of mesothelin targeted immunotoxin SS1P achieves single dosage complete regression of a human carcinoma in mice.

Mitchell Ho, I. Pastan, Jun Liu, 2007, Bioconjugate chemistry.

Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein

I. Pastan, B. Moss, T. Fuerst, 1988, Nature.

Pseudomonas exotoxin exhibits increased sensitivity to furin when sequences at the cleavage site are mutated to resemble the arginine‐rich loop of diphtheria toxin

M. Chiron, M. Ogata, M. Ogata, 1996, Molecular microbiology.

Recombinant Toxins: New Therapeutic Agents for Cancer

I. Pastan, U. Brinkmann, L. Pai, 1995, Annals of the New York Academy of Sciences.

Immunotoxins and Endocytosis

I. Pastan, M. Willingham, R. Pirker, 1987 .

Furin-mediated Cleavage of Pseudomonas Exotoxin-derived Chimeric Toxins*

M. Chiron, C. Fryling, D. FitzGerald, 1997, The Journal of Biological Chemistry.

Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P

I. Pastan, D. FitzGerald, Abid R Mattoo, 2013, PloS one.

Antitumor activity of an immunotoxin in a nude mouse model of human ovarian cancer.

I. Pastan, M. Willingham, R. Ozols, 1987, Cancer research.

[12] Construction of immunotoxins using Pseudomonas exotoxin A

D. FitzGerald, 1987 .

LL2-Fab' Induce Regression of Subcutaneous Human B-Cell Lymphoma in Mice1

I. Pastan, R. Kreitman, David, 2006 .

Generation of a potent chimeric toxin by replacement of domain III of Pseudomonas exotoxin with ricin A chain KDEL.

C. Pitcher, S. Fawell, L. Roberts, 1995, Bioconjugate chemistry.

Reduction of furin-nicked Pseudomonas exotoxin A: an unfolding story.

M. McKee, D. FitzGerald, 1999, Biochemistry.

Chimeric cytotoxin IL2-PE40 inhibits relapsing experimental allergic encephalomyelitis

I. Pastan, R. McCarron, J. Rose, 1991, Journal of Neuroimmunology.

Pseudomonas Exotoxin and Recombinant Immunotoxins Derived from It

I. Pastan, D. FitzGerald, 1993, Annals of the New York Academy of Sciences.

In vivo targeting of leukemic cells using diphtheria toxin fused to murine GM-CSF

A. Hagenbeek, I. Touw, R. Kreitman, 1998, Leukemia.

Characterization of a cellular protease that cleaves Pseudomonas exotoxin

V. Chaudhary, C. Fryling, M. Ogata, 1992, Infection and immunity.

Dual-Function Vaccine for Pseudomonas aeruginosa: Characterization of Chimeric Exotoxin A-Pilin Protein

R. Mrsny, R. Hertle, D. FitzGerald, 2001, Infection and Immunity.

Managing the TME to improve the efficacy of cancer therapy

A. Antignani, M. Bilotta, D. FitzGerald, 2022, Frontiers in Immunology.

Combination treatments with ABT‐263 and an immunotoxin produce synergistic killing of ABT‐263‐resistant small cell lung cancer cell lines

D. FitzGerald, Abid R Mattoo, 2013, International journal of cancer.

Recombinant toxins as novel therapeutic agents.

I. Pastan, D. Fitzgerald, V. Chaudhary, 1992, Annual review of biochemistry.

Antibody–Toxin and Growth Factor–Toxin Fusion Proteins

I. Pastan, R. Kreitman, D. FitzGerald, 2002 .

PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

I. Pastan, U. Brinkmann, L. Pai, 2001 .

Antitumor immunotoxin secretion by T cells: ABSolutely FABulous?

D. FitzGerald, 1997, Nature Biotechnology.

Recombinant immunotoxins for the treatment of cancer

I. Pastan, D. FitzGerald, 1996 .

Purification and Partial Characterization of an Interleukin 2-Pseudomonas Exotoxin Fusion Protein

I. Pastan, M. Gately, H. Lorberboum-Galski, 1988, Bio/Technology.

Pseudomonas exotoxin kills Drosophila S2 cells via apoptosis.

D. FitzGerald, Ashima Sharma, 2010, Toxicon : official journal of the International Society on Toxinology.

High Response Rate of Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia Includes Eradication of Minimal Residual Disease: Potential Importance for Outcome

W. Wilson, I. Pastan, M. Tallman, 2015 .

Pharmacokinetic Analysis Of Response In Hairy Cell Leukemia Treated By Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox

W. Wilson, I. Pastan, M. Stetler-Stevenson, 2013 .

Recombinant RFB4 single-chain immunotoxin that is cytotoxic towards CD22-positive cells.

I. Pastan, M. Chiron, E. Mansfield, 1997, Biochemical Society transactions.

Cytotoxic activities of recombinant immunotoxins composed of Pseudomonas toxin or diphtheria toxin toward lymphocytes from patients with adult T-cell leukemia.

T. Waldmann, I. Pastan, V. Chaudhary, 1993, Leukemia.

Antibody drug conjugates, targeting cancer-expressed EGFR, exhibit potent and specific antitumor activity.

A. Antignani, M. Bilotta, D. FitzGerald, 2022, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

Mutational analysis of domain I of Pseudomonas exotoxin. Mutations in domain I of Pseudomonas exotoxin which reduce cell binding and animal toxicity.

I. Pastan, S. Adhya, D. Fitzgerald, 1988, The Journal of biological chemistry.

Mucosal administration of a chimera composed of Pseudomonas exotoxin and the gp120 V3 loop sequence of HIV-1 induces both salivary and serum antibody responses.

A. Daugherty, R. Mrsny, C. Fryling, 1999, Vaccine.

Phase I Clinical Trial of the Anti-CD22 Immunotoxin CAT-8015 (HA22) for Pediatric Acute Lymphoblastic Leukemia (ALL).

C. Pui, I. Pastan, M. Stetler-Stevenson, 2009 .

The Development and Characterization of a Human Mesothelioma In Vitro 3D Model to Investigate Immunotoxin Therapy

K. Nagashima, Mitchell Ho, Jingli Zhang, 2011, PloS one.

Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis

I. Pastan, M. Willingham, R. Padmanabhan, 1983, Cell.

Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.

I. Pastan, D. Dimitrov, R. Morgan, 2013, Blood.

The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.

I. Pastan, D. FitzGerald, Xiufen Liu, 2013, Cancer research.

Immunotoxin therapy of cancer.

Ira Pastan, I. Pastan, R. Kreitman, 1993, Nature reviews. Cancer.

Immunotoxins: The Role of the Toxin †

D. Fitzgerald, A. Antignani, Antonella Antignani, 2013, Toxins.

Immunotoxin treatment of cancer.

I. Pastan, R. Kreitman, R. Hassan, 2007, Annual review of medicine.

Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia.

W. Wilson, I. Pastan, M. Stetler-Stevenson, 2001, The New England journal of medicine.

Cell-specific cargo delivery using synthetic bacterial spores

K. Ramamurthi, S. Hewitt, K. Tanner, 2020, bioRxiv.

Whole-genome RNAi screen highlights components of the endoplasmic reticulum/Golgi as a source of resistance to immunotoxin-mediated cytotoxicity

Rajarshi Guha, Eugen C. Buehler, Ira Pastan, 2015, Proceedings of the National Academy of Sciences.

Diphtheria toxin fused to granulocyte-macrophage colony-stimulating factor eliminates acute myeloid leukemia cells with the potential to initiate leukemia in immunodeficient mice, but spares normal hemopoietic stem cells.

A. Hagenbeek, B. Löwenberg, R. Kreitman, 1997, Blood.

Mesothelin Expression in Human Lung Cancer

Mitchell Ho, I. Pastan, M. Willingham, 2007, Clinical Cancer Research.

Generation of antibody-based therapeutics targeting the Idiotype of B-cell Malignancies.

Mitchell Ho, R. Kreitman, A. Antignani, 2018, Antibody therapeutics.

Immunotoxin therapy of cancer

Ira Pastan, I. Pastan, D. Fitzgerald, 2006, Nature Reviews Cancer.

BL22: A Milestone in Targeting CD22

I. Pastan, R. Kreitman, D. FitzGerald, 2017 .

ANTIBODY DERIVATIVES AS NEW THERAPEUTICS FOR HEMATOLOGIC MALIGNANCIES Immunotoxins for leukemia

I. Pastan, R. Kreitman, A. Wayne, 2014 .

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.

I. Pastan, D. Fitzgerald, R. Kreitman, 2011, Cancer research.

Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.

S. Hewitt, N. Simon, A. Antignani, 2016, Journal of the National Cancer Institute.

A rhlI 5′ UTR-Derived sRNA Regulates RhlR-Dependent Quorum Sensing in Pseudomonas aeruginosa

S. Gottesman, R. Sorek, C. Buchrieser, 2019, mBio.

Verapamil enhances the toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin and antitransferrin receptor with pseudomonas exotoxin

I. Pastan, M. Willingham, M. Gottesman, 1984, Journal of Cellular Physiology.

Immunotoxins

I. Pastan, M. Willingham, D. Fitzgerald, 1986, Cell.

Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers

N. Simon, D. FitzGerald, 2016, Toxins.

Conversion of Commensal Escherichia coli K-12 to an Invasive Form via Expression of a Mutant Histone-Like Protein

S. Adhya, S. Kar, D. FitzGerald, 2011, mBio.

Identification of tandem duplicate regulatory small RNAs in Pseudomonas aeruginosa involved in iron homeostasis.

S. Gottesman, M. Vasil, P. FitzGerald, 2004, Proceedings of the National Academy of Sciences of the United States of America.

'Characterization of monoclonal antibodies generated to the 287-302 amino acid loop of the human epidermal growth factor receptor'.

A. Antignani, D. FitzGerald, R. Sarnovsky, 2019, Antibody therapeutics.

Small RNA regulators and the bacterial response to stress.

N. Majdalani, S. Gottesman, K. M. Thompson, 2006, Cold Spring Harbor symposia on quantitative biology.

Characterization of the B Cell Epitopes Associated with a Truncated Form of Pseudomonas Exotoxin (PE38) Used to Make Immunotoxins for the Treatment of Cancer Patients1

James J. Vincent, I. Pastan, Byungkook Lee, 2006, The Journal of Immunology.

Sensitivity of human acute myeloid leukaemia to diphtheria toxin‐GM‐CSF fusion protein

A. Hagenbeek, I. Pastan, I. Touw, 1997, British journal of haematology.

Targeting Receptors on Cancer Cells with Protein Toxins

A. Antignani, Rong Qiu, M. Bilotta, 2020, Biomolecules.

Tofacitinib Suppresses Antibody Responses to Protein Therapeutics in Murine Hosts

I. Pastan, J. O’Shea, K. Ghoreschi, 2014, The Journal of Immunology.

A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.

I. Pastan, D. Fitzgerald, O. Chertov, 2009, Blood.

Cytotoxic activity of disulfide-stabilized recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) toward fresh malignant cells from patients with B-cell leukemias.

I. Pastan, M. Stetler-Stevenson, R. Kreitman, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Recombinant immunotoxins for treating cancer.

W. Wilson, I. Pastan, D. Fitzgerald, 2004, International journal of medical microbiology : IJMM.

Treatment of acute myelocytic leukemia with interleukin-6 Pseudomonas exotoxin fusion protein in a rat leukemia model.

A. Hagenbeek, I. Pastan, I. Touw, 1996, Leukemia.

Combining the Antimesothelin Immunotoxin SS1P With the BH3-mimetic ABT-737 Induces Cell Death in SS1P-resistant Pancreatic Cancer Cells

I. Pastan, D. Fitzgerald, A. Antignani, 2014, Journal of immunotherapy.

Mik-beta 1(Fv)-PE40, a recombinant immunotoxin cytotoxic toward cells bearing the beta-chain of the IL-2 receptor.

W. P. Schneider, T. Waldmann, I. Pastan, 1992, Journal of immunology.

Recombinant immunotoxins

I. Pastan, U. Brinkmann, L. Pai, 2005, Breast Cancer Research and Treatment.

Interdomain hydrolysis of a truncated Pseudomonas exotoxin by the human immunodeficiency virus-1 protease.

I. Pastan, A. Tomasselli, R. Heinrikson, 1990, The Journal of biological chemistry.

Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins

M. Ferrer, I. Pastan, R. Guha, 2016, PloS one.

Re-localization of Cellular Protein SRp 20 during Poliovirus Infection : Bridging a Viral IRES to the Host Cell

B. Semler, D. Fitzgerald, D. FitzGerald, 2011 .

Functional Expression of the Chicken Low Density Lipoprotein Receptor-related Protein in a Mutant Chinese Hamster Ovary Cell Line Restores Toxicity of Pseudomonas Exotoxin A and Degradation of α2-Macroglobulin*

R. McLeod, Yuwei Wang, J. Nimpf, 1998, The Journal of Biological Chemistry.

Conversion of Commensal Escherichia coli K-12 to an Invasive Form via Expression of a Mutant Histone-Like Protein

S. Adhya, S. Kar, D. FitzGerald, 2011, mBio.

Cytotoxic activities of a fusion protein comprised of TGFα and Pseudomonas exotoxin

I. Pastan, S. Adhya, D. Fitzgerald, 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins

N. Simon, R. Kreitman, A. Antignani, 2017, Oncogene.

Targeted diphtheria toxin to treat BPDCN.

D. FitzGerald, 2014, Blood.

Refined crystallographic structure of Pseudomonas aeruginosa exotoxin A and its implications for the molecular mechanism of toxicity.

P. Koehl, M. Dorywalska, J. Wedekind, 2001, Journal of molecular biology.

Furin regulates both the activation of Pseudomonas exotoxin A and the Quantity of the toxin receptor expressed on target cells

S. Leppla, D. Fitzgerald, V. M. Gordon, 1996, Infection and immunity.

Analgesia by deletion of spinal neurokinin 1 receptor expressing neurons using a bioengineered substance P-Pseudomonas exotoxin conjugate

M. Iadarola, A. Mannes, M. Sapio, 2017, Molecular pain.

Cytotoxic activity of chimeric proteins composed of acidic fibroblast growth factor and Pseudomonas exotoxin on a variety of cell types

I. Pastan, T. Hla, R. Forough, 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Proteases from human immunodeficiency virus and avian myeloblastosis virus show distinct specificities in hydrolysis of multidomain protein substrates

I. Pastan, A. Tomasselli, I. Reardon, 1990, Journal of virology.

Characterization of V3 Loop-Pseudomonas Exotoxin Chimeras

M. McKee, T. Wrin, A. Daugherty, 1998, The Journal of Biological Chemistry.

Expression of hepatocyte low-density lipoprotein receptor-related protein is post-transcriptionally regulated by extracellular matrix.

J. LaMarre, W. Marshall, S. Benn, 1998, Laboratory investigation; a journal of technical methods and pathology.

Resolution of Hairy Cell Leukemia Minimal Residual Disease by Both BRAF and Clone-Specific Real-Time Quantitative PCR (RQ-PCR) After Treatment with Moxetumomab Pasudotox.

W. Wilson, I. Pastan, M. Raffeld, 2012 .

Phase II trial of CAT-3888 (BL22) in chemo-resistant hairy cell leukemia

W. Wilson, I. Pastan, M. Stetler-Stevenson, 2007 .

Epithelial application of Pseudomonas aeruginosa exotoxin A results in a selective targeting to cells in the liver, spleen and lymph node.

A. Daugherty, R. Mrsny, D. FitzGerald, 2000, Journal of controlled release : official journal of the Controlled Release Society.

Elimination of infectious human immunodeficiency virus from human T-cell cultures by synergistic action of CD4-Pseudomonas exotoxin and reverse transcriptase inhibitors.

J. Weinstein, I. Pastan, B. Moss, 1990, Proceedings of the National Academy of Sciences of the United States of America.

A rapid method of cloning functional variable-region antibody genes in Escherichia coli as single-chain immunotoxins.

I. Pastan, M. Willingham, D. Fitzgerald, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin.

I. Pastan, D. Fitzgerald, W. Debinski, 1993, Cancer research.

Substitution of foreign protein sequences into a chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin

I. Pastan, D. Fitzgerald, W. Debinski, 1991, Molecular and cellular biology.

Antitumor activity in mice of an immunotoxin made with anti-transferrin receptor and a recombinant form of Pseudomonas exotoxin.

I. Pastan, M. Willingham, D. Fitzgerald, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Targeted toxin therapy for the treatment of cancer.

I. Pastan, D. Fitzgerald, D. FitzGerald, 1989, Journal of the National Cancer Institute.

Domain II mutants of Pseudomonas exotoxin deficient in translocation.

I. Pastan, M. Willingham, S. Adhya, 1989, The Journal of biological chemistry.

Cytotoxic activity of an interleukin 6-Pseudomonas exotoxin fusion protein on human myeloma cells.

I. Pastan, D. Fitzgerald, V. Chaudhary, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Activity of immunotoxins constructed with modified Pseudomonas exotoxin A lacking the cell recognition domain.

I. Pastan, S. Adhya, D. Fitzgerald, 1988, The Journal of biological chemistry.

Pseudomonas exotoxin contains a specific sequence at the carboxyl terminus that is required for cytotoxicity.

I. Pastan, D. Fitzgerald, V. Chaudhary, 1990, Proceedings of the National Academy of Sciences of the United States of America.

Recombinant toxins for cancer treatment.

I. Pastan, D. Fitzgerald, D. FitzGerald, 1991, Science.

Bacterial toxins as tools for mucosal vaccination.

M. McKee, A. Daugherty, R. Mrsny, 2002, Drug discovery today.

Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells.

I. Pastan, D. Fitzgerald, M. Gately, 1990, The Journal of biological chemistry.

Phase I Trial of Continuous Infusion Anti-Mesothelin Recombinant Immunotoxin SS1P

I. Pastan, R. Kreitman, R. Hassan, 2009, Clinical Cancer Research.

Expression of the interleukin 6 receptor and interleukin 6 in prostate carcinoma cells.

I. Pastan, R. Nordan, D. Fitzgerald, 1990, Cancer research.

Antitumor effects of interleukin 6-Pseudomonas exotoxin chimeric molecules against the human hepatocellular carcinoma, PLC/PRF/5 in mice.

I. Pastan, D. Fitzgerald, R. Kreitman, 1991, Cancer research.

Combining the Antimesothelin Immunotoxin SS1P With the BH3-mimetic ABT-737 Induces Cell Death in SS1P-resistant Pancreatic Cancer Cells

I. Pastan, A. Antignani, K. Hollevoet, 2014, Journal of immunotherapy.

B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice.

I. Pastan, M. Willingham, U. Brinkmann, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.

I. Pastan, R. Kreitman, A. Wayne, 2011, Cancer research.

A Phase 1 Study of Moxetumomab Pasudotox, An Anti-CD22 Recombinant Immunotoxin, In Relapsed/Refractory Hairy Cell Leukemia (HCL): Updated Results

I. Pastan, R. Lechleider, M. Tallman, 2010 .

Complete Remissions In 3 of 12 Patients with Pediatric Acute Lymphoblastic Leukemia (ALL) During Phase I Testing of the Anti-CD22 Immunotoxin Moxetumomab Pasudotox

C. Pui, I. Pastan, L. Silverman, 2010 .

Inhibition of antibody response to Pseudomonas exotoxin and an immunotoxin containing Pseudomonas exotoxin by 15-deoxyspergualin in mice.

I. Pastan, D. Fitzgerald, L. Pai, 1990, Cancer research.

The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin.

I. Pastan, D. FitzGerald, Xiufen Liu, 2013, Cancer research.

Antitumor effects of B3-PE and B3-LysPE40 in a nude mouse model of human breast cancer and the evaluation of B3-PE toxicity in monkeys.

I. Pastan, M. Willingham, D. Fitzgerald, 1992, Cancer research.

Characterization of immunotoxins active against ovarian cancer cell lines.

I. Pastan, M. Willingham, R. Ozols, 1985, The Journal of clinical investigation.

Cytotoxic activity of an interleukin 2-Pseudomonas exotoxin chimeric protein produced in Escherichia coli.

I. Pastan, S. Adhya, D. Fitzgerald, 1988, Proceedings of the National Academy of Sciences of the United States of America.

Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737

I. Pastan, Elizabeth Moskatel, R. Kreitman, 2011, Leukemia & lymphoma.

Immunotoxins for leukemia.

I. Pastan, R. Kreitman, A. Wayne, 2014, Blood.

Anti-Tac(Fv)-PE40, a single chain antibody Pseudomonas fusion protein directed at interleukin 2 receptor bearing cells.

I. Pastan, M. Gately, V. Chaudhary, 1990, The Journal of biological chemistry.